1. adverse eventadverse events; concomitant therapy; safety laboratory parameters (haematology; clinical chemistry; coagulation; andurinalysis); 12-lead ECG; vital signs; and physical examination.[Time Frame: To evaluate the safety and tolerability of AZD7442 administered IV or IM to healthy participants 18 to 55years of age.]2. PharmacokineticsAfter IV infusion: Ceoi; Cmax; Tmax; t1/2 z; AUClast; AUCinf; Vss; Vz and CL. After IM injection: Cmax; Tmax; t1/2 z;AUClast; AUCinf; extravascular systemic clearance (CL/F); bioavailability (F) and extravascular terminal phase volumeof distribution (Vz/F).[Time Frame: To evaluate Pharmacokinetics of AZD8895 and AZD1061 after single IV/IM administration of AZD7442.]

1. adverse eventadverse events; concomitant therapy; safety laboratory parameters (haematology; clinical chemistry; coagulation; andurinalysis); 12-lead ECG; vital signs; and physical examination.[Time Frame: To evaluate the safety and tolerability of AZD7442 administered IV or IM to healthy participants 18 to 55years of age.]2. PharmacokineticsAfter IV infusion: Ceoi; Cmax; Tmax; t1/2 z; AUClast; AUCinf; Vss; Vz and CL. After IM injection: Cmax; Tmax; t1/2 z;AUClast; AUCinf; extravascular systemic clearance (CL/F); bioavailability (F) and extravascular terminal phase volumeof distribution (Vz/F).[Time Frame: To evaluate Pharmacokinetics of AZD8895 and AZD1061 after single IV/IM administration of AZD7442.]